Technology News and Research

RSS

Organovo 2011 total revenues increase 61% to $968,513

Organovo Holdings, Inc., a three-dimensional biology company focused on delivering breakthrough 3D bioprinting technology, today reported the financial results for the year ended December 31, 2011.

3 Apr 2012

FDA clears Fenwal's TPE on the Amicus separator

The U.S. Food and Drug Administration has cleared Fenwal to market a therapeutic plasma exchange protocol for the company's Amicus separator, Fenwal announced today.

3 Apr 2012

PolyTherics, Spirogen enter research collaboration to produce novel ADCs for treatment of cancer

PolyTherics Limited, a provider of solutions to enable the development of better biopharmaceuticals, and Spirogen Limited, a leading oncology-focused company developing DNA sequence-targeted agents, announce that they have formed a research collaboration to develop antibody drug conjugates that combine PolyTherics' proprietary site-specific conjugation chemistry with Spirogen's highly potent novel cytotoxic drugs to produce novel ADCs for the treatment of cancer.

2 Apr 2012

Special fatty molecules pave novel way to treat infections, autoimmune diseases, allergies and cancer

An international research team led by scientists from Singapore Immunology Network (SIgN) under the Agency of Science, Technology and Research (A*STAR) discovered that a special class of fatty molecules is essential for activating a unique group of early-responding immune cells.

2 Apr 2012

New technology prevents stone migration during procedures to retrieve urinary stones

Boston Scientific Corporation announces the launch of its BackStop Gel, a new technology designed to prevent stone migration during procedures used to break up and retrieve urinary stones.

2 Apr 2012

Eisai, University of Kansas grant water-soluble pro-drug technology patent to OneWorld Health

OneWorld Health (OWH), a nonprofit that develops lifesaving medicines for neglected diseases, announced that it has signed a nonexclusive patent agreement with Eisai Co., Ltd., for a water-soluble pro-drug technology patent. OWH will use the pro-drug technology to advance development of iOWH032, its new drug to treat acute secretory diarrhea.

2 Apr 2012

Biotage adds Isolera Spektra to Flash Chromatography product line

Biotage, a leading global supplier of solutions and technology for analytical and medicinal chemistry, introduced Isolera Spektra. The new Isolera Spektra expands the scope of application of Biotage's market-leading Flash Chromatography product line by increasing efficiency with significant solvent and time saving capabilities as well as enabling purity assessment technology.

2 Apr 2012

New diagnostic test for Trichomonas vaginalis

Medical Diagnostic Laboratories, L.L.C. is a CLIA certified infectious disease laboratory which specializes in high-complexity, state-of-the-art, automated DNA-based molecular analyses.

2 Apr 2012

RainDance introduces new panel for cancer mutation screening

RainDance Technologies, Inc., the Digital Biology company, today announced the worldwide availability of its new panel for cancer mutation screening research using any next-generation sequencing (NGS) system.

2 Apr 2012

Spacelabs Healthcare receives FDA 510(k) clearance for Arkon anesthesia delivery system

Spacelabs Healthcare has received clearance under Section 510(k) from the U.S. Food and Drug Administration to market Arkon, a high-performance anesthesia delivery system designed from the anesthesiologist's perspective.

2 Apr 2012

Life Technologies expands TaqMan Mutation Detection Assays

Life Technologies Corporation today announced the expansion to its TaqMan Mutation Detection Assays -- highly sensitive and novel molecular analysis research tools designed to detect an additional 241 of the most common mutations in 21 cancer genes.

2 Apr 2012

NanoViricides reports positive pre-IND meeting with USFDA for FluCide

NanoViricides, Inc. announced today that its previously announced pre-IND Meeting was held with the USFDA on March 29th, 2012, as scheduled. This pre-IND meeting focused on FluCide, designated as NV-INF-1, the Company's novel anti-influenza drug.

2 Apr 2012

Blocking PRC2 protein may help protect against AML

Scientists at Cold Spring Harbor Laboratory have identified a candidate drug target for treating acute myeloid leukemia, a white blood cell cancer that proliferates out of control in the bone marrow.

2 Apr 2012

Neurotechnology releases new versions of embedded SDKs

Neurotechnology, a provider of high-precision biometric identification and object recognition technologies, has released new versions of the company's product line of Software Development Kits (SDKs) for biometric fingerprint, face, iris and voice identification and object recognition.

2 Apr 2012

ProteinSimple introduces Sally Western Blot

ProteinSimple today introduced Sally as the next member of the revolutionary Simple Western product family. Sally eliminates a critical bottleneck in large-scale protein research and biopharmaceutical development – manual Western Blot analysis. With Sally, researchers can perform 96 Simple Westerns in a single automated experiment.

From ProteinSimple 2 Apr 2012

Encision completes private placement of 1,500,000 shares of common stock

Encision Inc., a medical device company owning patented surgical technology that is emerging as a standard of care in minimally-invasive surgery, announced today that it had completed a private placement of 1,500,000 shares of its common stock.

2 Apr 2012

Therakos introduces Lighting Up Lives campaign for patients with immune diseases

Therakos, Inc., a pioneer in the development of an innovative immune modulation therapy called extracorporeal photopheresis (ECP), today launched Lighting Up Lives, a 25-year anniversary campaign and year-long global initiative that honours the lives of patients with serious immune diseases impacted by ECP, as well as the healthcare professionals, caregivers and treatment centres that support them every step of the way.

2 Apr 2012

Scientists use DNA sequencing to identify 'driver' mutations in cancer

Scientists at Washington University School of Medicine in St. Louis are using powerful DNA sequencing technology not only to identify mutations at the root of a patient's tumor - considered key to personalizing cancer treatment - but to map the genetic evolution of disease and monitor response to treatment.

2 Apr 2012

Dyax, GE Healthcare partner to develop and commercialize c-Met imaging peptides

GE Healthcare, a unit of GE, and Dyax Corp. today announced a licensing agreement for the development and commercialization of peptides binding to c-Met, which provides upfront, milestone, and royalty payments to Dyax.

2 Apr 2012

New breast cancer gene mutation discovered

A large international study led by University of Melbourne researchers has identified a mutation linked to breast cancer attached to the newly identified gene, called XRCC2. Lead researcher Melissa Southey said the discovery, using high-speed technology, would hopefully mean that more gene mutations responsible for causing breast cancer could be rapidly identified in the next few years.

1 Apr 2012